| Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection (NCT05413850) | Blue Earth Therapeutics Ltd | 2022-07-20 |
| Effectiveness Evaluation of a Self-management Program for Prostate Cancer Survivors (NCT05335967) | National Taipei University of Nursing and Health Sciences | 2022-05-20 |
| The Role of the Seven Sweeps in the Prevention of the Prostate Cancer Among Those With a Positive Family History (NCT05506735) | University of Baghdad | 2022-05-01 |
| Single Dose Versus Double Dose Tamsulosin in Management of Moderate and Severe LUTS Due to BPH (NCT05834270) | Menoufia University | 2022-05-01 |
| EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC (NCT05150236) | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 2022-04-29 |
| A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) (NCT05288166) | Eli Lilly and Company | 2022-04-14 |
| Contributions of a Paramedical Approach in the Prevention and Treatment of Side Effects Associated With Radical Prostatectomy (NCT05266313) | University Hospital Center of Martinique | 2022-03-31 |
| A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (NCT05295927) | Janssen Research & Development, LLC | 2022-03-23 |
| Lymphedema After Urologic Surgery (NCT05264337) | Vastra Gotaland Region | 2022-03-14 |
| Imperial Prostate 6 - Cancer Histology Artificial Intelligence Reliability Study. (NCT05228197) | Imperial College London | 2022-03-11 |
| Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients (NCT05068180) | RenJi Hospital | 2021-10-05 |
| Study of Diagnostic Performance of [18F]CTT1057 in BCR (NCT04838613) | Novartis Pharmaceuticals | 2021-09-30 |
| A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants (NCT05022849) | Janssen Research & Development, LLC | 2021-09-28 |
| Identification of Prostate Cancer Specific Markers in Patients Compared to Healthy Participants (NCT04964271) | Tethis S.p.A. | 2021-09-09 |
| Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection (NCT04838626) | Novartis Pharmaceuticals | 2021-09-07 |
| The Application Value of 18F-prostate-specific Membrane Antigen PET/CT in Prostate Cancer (NCT04521894) | First Affiliated Hospital Xi'an Jiaotong University | 2021-08-22 |
| A Study of CC-90011 and Comparators in Participants With Prostate Cancer (NCT04628988) | Celgene | 2021-07-28 |
| A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer (NCT04898634) | Janssen Research & Development, LLC | 2021-07-13 |
| Positron Emission Tomography (PET) Imaging of Participants With Confirmed Prostate Cancer Using 64Cu-SAR-bisPSMA (PROPELLER) (NCT04839367) | Clarity Pharmaceuticals Ltd | 2021-07-13 |
| Randomized Pilot Study of Radiosurgery for the Treatment of Non-metastatic Prostate Cancer (NCT05123391) | Pontificia Universidad Catolica de Chile | 2021-06-22 |
| 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer (NCT04689828) | Novartis Pharmaceuticals | 2021-06-15 |
| An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) (NCT04720157) | Novartis Pharmaceuticals | 2021-06-09 |
| 68Ga-PSMA PET in the Prostate Cancer (NCT04967001) | Xijing Hospital | 2021-06-01 |
| Verification of Shear Wave Elastography for DEtection of Prostate Cancer (NCT04836949) | Yonsei University | 2021-05-03 |
| Combined PSMA PET/MRI for Detection of Lymph Node Metastases in High-risk Prostate Cancer Patients (NCT04790968) | Norwegian University of Science and Technology | 2021-04-28 |
| High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy (NCT04461509) | Alessandro D'Agnolo | 2021-04-06 |
| ComCancer: Use of Let's Discuss Health Website by Patients With Prostate Cancer Undergoing Radiation Oncology Treatment (NCT05787145) | Ciusss de L'Est de l'Île de Montréal | 2021-03-10 |
| Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer (NCT04736199) | Bayer | 2021-02-23 |
| Adjuvant Apalutamide in Subjects With High-risk Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy (NCT04295447) | Universität Münster | 2020-12-10 |
| Evaluation of Atherosclerotic Plaques in Abdominal CT Studies (NCT04652973) | National Institutes of Health Clinical Center (CC) | 2020-11-19 |
| A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer (NCT04577833) | Janssen Research & Development, LLC | 2020-11-13 |
| A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer (NCT04557059) | Janssen Pharmaceutica N.V., Belgium | 2020-11-12 |
| A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer (NCT04644770) | Janssen Research & Development, LLC | 2020-11-12 |
| Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension (NCT04907227) | Merck Sharp & Dohme LLC | 2020-09-23 |
| Intestinal Microbiota in Prostate Cancer Patients as a Biomarker for Radiation-INduced Toxicity (IMPRINT) (NCT04638049) | University Hospital, Ghent | 2020-08-25 |
| A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases (NCT04523207) | Janssen Research & Development, LLC | 2020-08-19 |
| Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy (NCT04430192) | Peter MacCallum Cancer Centre, Australia | 2020-08-06 |
| Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer (NCT04085991) | Sir Mortimer B. Davis - Jewish General Hospital | 2020-07-31 |
| Prevalence of HRR-related Genes Mutations and Prognosis in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients in Real World Setting (NCT04425200) | AstraZeneca | 2020-07-29 |
| Effectiveness of 68Ga-PSMA PET/MRI for Improving the Detection of csPCa in Lesions With PI-RADS Score 3 (NCT04573179) | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 2020-07-01 |
| Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer (NCT04428788) | Celgene | 2020-06-22 |
| PSMA-PET and MRI for Detection of Recurrent Prostate Cancer After Radical Treatment (NCT04298112) | Norwegian University of Science and Technology | 2020-05-01 |
| Multiparametric MRI in Men With Prostate Cancer Enrolled in Active Surveillance (NCT03648359) | Herlev Hospital | 2020-05-01 |
| P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) (NCT04249947) | Poseida Therapeutics, Inc. | 2020-02-28 |
| Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients (NCT04248621) | Wonju Severance Christian Hospital | 2020-01-23 |
| A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC) (NCT04108208) | Janssen Research & Development, LLC | 2019-12-17 |
| Radical Prostatectomy Versus Radical Radiotherapy for Locally Advanced Prostate Cancer (NCT04093375) | Tongji Hospital | 2019-11-01 |
| Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging (NCT04017104) | British Columbia Cancer Agency | 2019-11-01 |
| Study of ORIC-101 in Combination With Enzalutamide (NCT04033328) | ORIC Pharmaceuticals | 2019-10-28 |
| Measurement of Circulating Tumor Cells in Prostate Cancer (NCT04101305) | Sormland County Council, Sweden | 2019-09-01 |
| Rectal Gas Removal Through Small Catheter Placement Prior to MRI of the Prostate (NCT03987737) | Universitaire Ziekenhuizen KU Leuven | 2019-08-01 |
| Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641) (NCT03834493) | Merck Sharp & Dohme LLC | 2019-07-28 |
| A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan (NCT04034095) | Janssen Pharmaceutical K.K. | 2019-07-08 |
| A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy (NCT03767244) | Janssen Research & Development, LLC | 2019-06-11 |
| Multimedia-based Hormonal Therapy Information Program for Patients With Prostate Cancer (NCT04693910) | National Taipei University of Nursing and Health Sciences | 2019-05-13 |
| Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) (NCT03834519) | Merck Sharp & Dohme LLC | 2019-05-02 |
| Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921) (NCT03834506) | Merck Sharp & Dohme LLC | 2019-05-02 |
| Treatment Satisfaction With Ra-223 in Japan (NCT03315260) | Bayer | 2019-04-11 |
| Men at High Genetic Risk for Prostate Cancer (NCT03805919) | National Cancer Institute (NCI) | 2019-03-27 |
| Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer (NCT03822845) | Michael Graham PhD, MD | 2019-03-01 |
| 18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer (NCT03824275) | Columbia University | 2019-02-12 |
| Moderately Hypofractionated Radiotherapy for Prostate Cancer. (NCT03827616) | Tatarstan Cancer Center | 2019-01-25 |
| The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females (NCT03436745) | National Cancer Institute (NCI) | 2019-01-22 |
| PSMA PET/CT for Biochemical Recurrence Detection in Patients With Prostate Cancer (NCT04983459) | University Hospital, Brest | 2018-10-01 |
| A Pilot Study of Hormonal Therapy Combined With Central Memory T Cells (Tcm) for Patients With Advanced Prostate Cancer (NCT03587285) | Guangzhou University of Traditional Chinese Medicine | 2018-09-23 |
| A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer (NCT03523442) | Janssen Research & Development, LLC | 2018-08-31 |
| A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment (NCT03572387) | Icahn School of Medicine at Mount Sinai | 2018-08-20 |
| Mirabegron for Treatment of Erectile Dysfunction in Patients With LUTS Secondry to BPH: A Randomized Study (NCT03600766) | Mansoura University | 2018-08-01 |
| Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines (NCT03481816) | National Cancer Institute (NCI) | 2018-07-24 |
| An Electronic Registry to Improve Adherence to Active Surveillance Monitoring at a Safety-net Hospital (NCT03553732) | University of California, San Francisco | 2018-07-01 |
| Local Treatment With RP for Newly-diagnosed mPCa (NCT02138721) | University Hospital, Ghent | 2018-06-28 |
| Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer (NCT03565835) | Montefiore Medical Center | 2018-06-13 |
| Biomarkers in Prostate Cancer Treated With SRP Following Failure of FAT (NCT03533998) | Institut Mutualiste Montsouris | 2018-05-31 |
| A Study of Participants With Advanced Prostate Cancer in Canada (NCT03501173) | Janssen Inc. | 2018-04-12 |
| Learning Curve of Digital Rectal Examination for Prostate Cancer Among Internship (NCT03479359) | Changhai Hospital | 2018-02-26 |
| Exercise Prescription Dose for Castration Resistance Prostate Cancer Patients (NCT03526562) | University Hospital, Ghent | 2018-01-15 |
| Functional MR-guided Stereotactic Body Radiation Therapy of Prostate Cancer (NCT01976962) | CancerCare Manitoba | 2018-01-10 |
| Effect of PEEP on Arterial Oxygen Partial Pressure in Elderly Patients With Lithotomy Position Using LMA Supreme™ (NCT03390127) | Asan Medical Center | 2018-01-05 |
| Innovations in the Treatment of Sexual Health Post Prostate Cancer Treatment: Comparing Mindfulness vs. CBT (NCT03365518) | University of British Columbia | 2017-12-29 |
| Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer (NCT03261999) | Foresee Pharmaceuticals Co., Ltd. | 2017-09-26 |
| Multiparametric Ultrasound Imaging in Prostate Cancer (NCT03101176) | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 2017-09-07 |
| Machine-learning Optimization for Prostate Brachytherapy Planning (NCT02943824) | Sunnybrook Health Sciences Centre | 2017-08-24 |
| Drug-drug-interaction Study to Assess the Effect of Darolutamide on the Pharmacokinetics of Probe Substrates of CYP3A4 and P-gp in Healthy Male Volunteers (NCT03237416) | Bayer | 2017-08-02 |
| Prostate Impendance Test Project (NCT03428087) | University of Pisa | 2017-07-01 |
| The Assessment of the Feasibility of a Home Based Exercise Programme in the Older Patient Following Major Surgery (NCT03064308) | University of Nottingham | 2017-06-26 |
| 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer (NCT03173924) | National Cancer Institute (NCI) | 2017-06-06 |
| Infectious Outcomes of Povidone-iodine Rectal Cleansing Plus Formalin Disinfection of Needle During Prostate Biopsy (NCT03879486) | Hospital de Transplante Doutor Euryclides de Jesus Zerbini | 2017-05-31 |
| Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT (NCT03007732) | David Oh | 2017-05-17 |
| Genetic Analysis of Prostate Cancer to Identify Predictive Markers of Disease Relapse or Metastatic Evolution (NCT03421015) | University Hospital, Lille | 2017-05-01 |
| Clinic Study of 18F-Al-NOTA-MATBBN in Cancer Diagnostics (NCT03094897) | Wuxi No. 4 People's Hospital | 2017-04-20 |
| PSMA PET/CT for Assessment of Recurrent Prostate Cancer (NCT02899312) | British Columbia Cancer Agency | 2017-03-16 |
| PK, PD, Tolerability and Safety of MDPK67b in Healthy Volunteers (NCT04839120) | Med Discovery SA | 2017-02-21 |
| Contrast Enhanced MRI of the Prostate (NCT02245282) | OHSU Knight Cancer Institute | 2017-02-10 |
| Incidence of Second Primary Malignancies in Prostate Cancer Patients With Bone Metastases - an Observational Retrospective Cohort Study in Sweden (NCT02963675) | Bayer | 2016-11-15 |
| Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer (NCT02506114) | Lawrence Fong | 2016-10-06 |
| A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE) (NCT02924766) | Janssen Research & Development, LLC | 2016-10-03 |
| Establishment and Clinical Assessment of a Prostate Cancer (PCa) Risk Model Based on the Updated Circulating Tumor Cell (CTC) Detection Technique (NCT02940977) | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | 2016-10-01 |
| A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations (NCT02950064) | Placon Therapeutics | 2016-09-01 |
| A Prospective Compliance Registry for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (NCT02905201) | Janssen Research & Development, LLC | 2016-09-01 |
| An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies (NCT02854436) | Janssen Research & Development, LLC | 2016-08-31 |